Skip to main content
Top
Literature
1.
go back to reference Perentes Y, van Tran T, Sickenberg M, Herbort CP (2005) Subretinal neovascular membranes complicating uveitis: frequency, treatments, and visual outcome. Ocul Immunol Inflamm 13:219–224PubMedCrossRef Perentes Y, van Tran T, Sickenberg M, Herbort CP (2005) Subretinal neovascular membranes complicating uveitis: frequency, treatments, and visual outcome. Ocul Immunol Inflamm 13:219–224PubMedCrossRef
2.
go back to reference Baxter SL, Pistilli M, Pujari SS, Liesegang TL, Suhler EB, Thorne JE, Foster CS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Kempen JH (2013) Risk of choroidal neovascularization among the uveitides. Am J Ophthalmol 156:468–477PubMedCrossRef Baxter SL, Pistilli M, Pujari SS, Liesegang TL, Suhler EB, Thorne JE, Foster CS, Jabs DA, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Kempen JH (2013) Risk of choroidal neovascularization among the uveitides. Am J Ophthalmol 156:468–477PubMedCrossRef
3.
go back to reference Neri P, Lettieri M, Fortuna C, Manoni M, Giovannini A (2009) Inflammatory choroidal neovascularization. Middle East Afr J Ophthalmol 16:245–251PubMedCentralPubMed Neri P, Lettieri M, Fortuna C, Manoni M, Giovannini A (2009) Inflammatory choroidal neovascularization. Middle East Afr J Ophthalmol 16:245–251PubMedCentralPubMed
4.
go back to reference Mansour AM, Arevalo JF, Fardeau C, Hrisomalos EN, Chan WM, Lai TY, Ziemssen F, Ness T, Sibai AM, Mackensen F, Wolf A, Hrisomalos N, Heiligenhaus A, Spital G, Jo Y, Gomi F, Ikuno Y, Akesbi J, LeHoang P, Adan A, Mahendradas P, Khairallah M, Guthoff R, Ghandour B, Küçükerdönmez C, Kurup SK (2012) Three-year visual and anatomic results of administrating intravitreal bevacizumab in inflammatory ocular neovascularization. Can J Ophthalmol 47:269–274PubMedCrossRef Mansour AM, Arevalo JF, Fardeau C, Hrisomalos EN, Chan WM, Lai TY, Ziemssen F, Ness T, Sibai AM, Mackensen F, Wolf A, Hrisomalos N, Heiligenhaus A, Spital G, Jo Y, Gomi F, Ikuno Y, Akesbi J, LeHoang P, Adan A, Mahendradas P, Khairallah M, Guthoff R, Ghandour B, Küçükerdönmez C, Kurup SK (2012) Three-year visual and anatomic results of administrating intravitreal bevacizumab in inflammatory ocular neovascularization. Can J Ophthalmol 47:269–274PubMedCrossRef
5.
go back to reference Arevalo JF, Adan A, Berrocal MH, Espinoza JV, Maia M, Wu L, Roca JA, Quiroz-Mercado H, Ruiz-Moreno JM, Serrano MA, Pan-American Collaborative Retina StudyGroup (2011) Intravitreal bevacizumab for inflammatory choroidal neovascularization: results from the Pan-American Collaborative Retina Study Group at 24 months. Retina 31:353–363PubMedCrossRef Arevalo JF, Adan A, Berrocal MH, Espinoza JV, Maia M, Wu L, Roca JA, Quiroz-Mercado H, Ruiz-Moreno JM, Serrano MA, Pan-American Collaborative Retina StudyGroup (2011) Intravitreal bevacizumab for inflammatory choroidal neovascularization: results from the Pan-American Collaborative Retina Study Group at 24 months. Retina 31:353–363PubMedCrossRef
6.
go back to reference Tran TH, Fardeau C, Terrada C, Ducos De Lahitte G, Bodaghi B, Lehoang P (2008) Intravitreal bevacizumab for refractory choroidal neovascularization (CNV) secondary to uveitis. Graefes Arch Clin Exp Ophthalmol 246:1685–1692PubMedCrossRef Tran TH, Fardeau C, Terrada C, Ducos De Lahitte G, Bodaghi B, Lehoang P (2008) Intravitreal bevacizumab for refractory choroidal neovascularization (CNV) secondary to uveitis. Graefes Arch Clin Exp Ophthalmol 246:1685–1692PubMedCrossRef
7.
go back to reference Rouvas A, Petrou P, Douvali M, Ntouraki A, Vergados I, Georgalas I, Markomichelakis N (2011) Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization. Retina 31:871–879PubMedCrossRef Rouvas A, Petrou P, Douvali M, Ntouraki A, Vergados I, Georgalas I, Markomichelakis N (2011) Intravitreal ranibizumab for the treatment of inflammatory choroidal neovascularization. Retina 31:871–879PubMedCrossRef
8.
go back to reference Mansour AM, Mackensen F, Mahendradas P, Khairallah M, Lai TY, Bashshur Z (2012) Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization. Clin Ophthalmol 6:1233–1237PubMedCentralPubMedCrossRef Mansour AM, Mackensen F, Mahendradas P, Khairallah M, Lai TY, Bashshur Z (2012) Five-year visual results of intravitreal bevacizumab in refractory inflammatory ocular neovascularization. Clin Ophthalmol 6:1233–1237PubMedCentralPubMedCrossRef
9.
go back to reference Freund KB, Mrejen S, Gallego-Pinazo R (2013) An update on the pharmacotherapy of neovascular age-related macular degeneration. Expert Opin Pharmacother 14:1017–1028PubMedCrossRef Freund KB, Mrejen S, Gallego-Pinazo R (2013) An update on the pharmacotherapy of neovascular age-related macular degeneration. Expert Opin Pharmacother 14:1017–1028PubMedCrossRef
10.
go back to reference Kumar N, Marsiglia M, Mrejen S, Fung AT, Slakter J, Sorenson J, Freund KB (2013) Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 33:1605–1612PubMedCrossRef Kumar N, Marsiglia M, Mrejen S, Fung AT, Slakter J, Sorenson J, Freund KB (2013) Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 33:1605–1612PubMedCrossRef
Metadata
Title
Aflibercept for inflammatory choroidal neovascularization with persistent fluid on intravitreal ranibizumab therapy
Authors
Pablo Hernández-Martínez
Rosa Dolz-Marco
Marta Alonso-Plasencia
Rodrigo Abreu-Gonzalez
Publication date
01-08-2014
Publisher
Springer Berlin Heidelberg
Published in
Graefe's Archive for Clinical and Experimental Ophthalmology / Issue 8/2014
Print ISSN: 0721-832X
Electronic ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-014-2634-2

Other articles of this Issue 8/2014

Graefe's Archive for Clinical and Experimental Ophthalmology 8/2014 Go to the issue